CClinicalTrials.gg
Not yet recruitingNCT07766681BREATHUpdated Aug 14, 2026

Epidural Spinal Cord Stimulation for Respiratory Recovery in Brain Injury

An interventional study of Epidural Electrode Implantation in Brain Injuries and Respiratory Failure, sponsored by Zhongda Hospital. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Zhongda Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 74 Years
Sex
All
01

Study summary

Patients with severe brain injury may develop impaired respiratory drive, diaphragm dysfunction, prolonged mechanical ventilation, and difficulty recovering spontaneous breathing. Epidural spinal cord stimulation may activate preserved spinal respiratory circuits and improve respiratory muscle activity. This prospective, single-center, non-randomized, single-arm exploratory study will enroll 10 patients with stroke or traumatic brain injury who have impaired consciousness and require invasive mechanical ventilation. Participants will undergo epidural spinal cord stimulation in addition to standard clinical care. Diaphragmatic electrical activity, respiratory function, diaphragm ultrasound findings, diaphragm electromyography, duration of mechanical ventilation, pulmonary infection, length of stay, mortality, safety events, and 6-month neurological outcome will be assessed. The study aims to evaluate the safety and preliminary efficacy of epidural spinal cord stimulation for improving respiratory function after brain injury.

Read the detailed description

Severe central nervous system injury, including stroke and traumatic brain injury, may impair respiratory drive and disrupt descending pathways between brainstem respiratory centers and spinal respiratory motor networks. This can lead to diaphragm weakness, ineffective cough, secretion retention, prolonged mechanical ventilation, pulmonary infection, and difficulty with ventilator liberation.

Epidural spinal cord stimulation is a neuromodulation approach that may increase the excitability of preserved spinal neural circuits and facilitate respiratory motor output. Preclinical and early clinical evidence suggests that spinal stimulation can enhance respiratory muscle activation and improve ventilatory performance.

This study is a prospective, single-center, interventional, non-randomized, single-arm exploratory trial. Ten adults with imaging-confirmed stroke or traumatic brain injury, a Glasgow Coma Scale score of 3 to 8, and a requirement for invasive mechanical ventilation for at least 24 hours will be enrolled. All participants will undergo epidural spinal cord stimulation in addition to standard treatment. Respiratory physiological measurements will be obtained before and after stimulation. Participants will be followed until hospital discharge and subsequently assessed for survival and neurological outcome at 6 months after injury.

The study will evaluate changes in diaphragmatic electrical activity and other respiratory parameters, as well as pulmonary infection, duration of mechanical ventilation, intensive care unit and hospital length of stay, in-hospital mortality, neurological outcome, and intervention-related adverse events.

02

Conditions studied

  • Brain Injuries
  • Respiratory Failure

Keywords

  • Epidural spinal cord stimulation
  • Respiratory failure
  • Diaphragmatic electrical activity
03

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 to 74 years. Body mass index less than 30 kg/m². Imaging-confirmed stroke or traumatic brain injury. Glasgow Coma Scale score of 3 to 8, with relatively stable vital signs. Requirement for invasive mechanical ventilation through an oral or nasal endotracheal tube or tracheostomy for at least 24 hours.

Written informed consent provided by the participant's legally authorized representative; if the participant regains decision-making capacity, continued participation will be reconfirmed with the participant.

Willingness and ability of the participant or legally authorized representative to comply with the study intervention and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  • Suspected or confirmed infection at the planned electrode implantation site, severe uncontrolled systemic infection, known metal allergy relevant to the implanted device, or uncontrolled intracranial hypertension.

Respiratory failure primarily attributable to severe pneumonia, pulmonary contusion, pneumothorax, hemothorax, chronic obstructive pulmonary disease with respiratory failure, severe asthma, or a requirement for home oxygen therapy within the previous 6 months.

New York Heart Association class III or IV heart failure or presence of an implanted cardiac pacemaker.

Severe hepatic dysfunction, including Child-Pugh class C, severe renal dysfunction with estimated glomerular filtration rate ≤30 mL/min/1.73 m², or dialysis dependence.

Status epilepticus or active convulsions. Cervical spinal cord injury, other spinal cord injury, major chest wall deformity, myasthenia, or respiratory dysfunction primarily caused by brainstem injury.

Severe psychiatric or pre-existing neurological or cognitive disorders that would interfere with study evaluation or completion, including amyotrophic lateral sclerosis, dementia, Parkinson disease, Huntington disease, or another clinically significant central nervous system disorder unrelated to the index brain injury.

Expected survival of 72 hours or less, or a decision to withhold endotracheal intubation, cardiopulmonary resuscitation, or other life-sustaining treatment.

Pregnancy or breastfeeding. Any other condition that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with completion of the study.

04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Epidural Spinal Cord Stimulation

    Participants will receive epidural spinal cord stimulation in addition to standard neurosurgical, neurocritical care, mechanical ventilation, airway management, and rehabilitation treatment. Respiratory physiological measurements will be obtained before and after stimulation.

    Procedure: Epidural Electrode Implantation

Interventions

  • ProcedureEpidural Electrode Implantation

    Participants will undergo surgical implantation of an epidural spinal cord stimulation electrode under anesthesia. The electrode will be positioned at the spinal level specified in the final surgical protocol and connected to a stimulation system.

05

What researchers measure

Primary outcomes

  1. Change in Peak Electrical Activity of the Diaphragm From Before to After Spinal Cord Stimulation

    Peak electrical activity of the diaphragm will be measured using an electrical activity of the diaphragm catheter. The change from the pre-stimulation value to the post-stimulation value will be reported in microvolts (μV).

    Time frame: Immediately before stimulation and within 1 hour after stimulation, upto 30 days

  2. Change in Diaphragmatic Electrical Activity Frequency From Before to After Spinal Cord Stimulation

    The frequency of diaphragmatic electrical activity signals will be measured using an electrical activity of the diaphragm catheter. The change from before to after stimulation will be reported as events per minute.

    Time frame: Immediately before stimulation and within 1 hour after stimulation, upto 30 days

Secondary outcomes

  1. Change in the Frequency of Diaphragmatic Electrical Activity Signals With Peak Amplitude of at Least 3 μV

    The number of diaphragmatic electrical activity signals with a peak amplitude of at least 3 μV will be determined using an electrical activity of the diaphragm catheter. The change from before to after stimulation will be reported as events per minute.

    Time frame: Immediately before stimulation and within 1 hour after stimulation, upto 30 days

  2. Change in the Frequency of Spontaneous Inspiratory Efforts Detected by Diaphragmatic Electrical Activity

    Spontaneous inspiratory efforts generated by the participant's neural respiratory drive will be detected using an electrical activity of the diaphragm catheter. Ventilator-delivered breaths without a corresponding diaphragmatic electrical activity signal will not be counted. The change from before to after stimulation will be reported as inspiratory efforts per minute.

    Time frame: Immediately before stimulation and within 1 hour after stimulation, upto 30 days

  3. Spontaneous Respiratory Rate

    The participant's spontaneous respiratory rate will be determined from respiratory monitoring and reported as breaths per minute. Ventilator-mandated breaths will be excluded.

    Time frame: Immediately before stimulation and within 1 hour after stimulation, upto 30 days

  4. Change in Tidal Volume From Before to After Spinal Cord Stimulation

    Tidal volume will be measured using the mechanical ventilator under standardized ventilator settings and reported in milliliters (mL).

    Time frame: Immediately before stimulation and within 1 hour after stimulation, upto 30 days

  5. Diaphragmatic Excursion

    Diaphragmatic excursion will be measured by bedside M-mode ultrasonography with the participant in the supine position. Values will be reported in millimeters (mm).

    Time frame: Immediately before stimulation and within 1 hour after stimulation upto 30 days

  6. Diaphragm Thickening Fraction

    Diaphragm thickening fraction will be calculated from inspiratory and expiratory diaphragm thickness measured by bedside ultrasonography and reported as a percentage.

    Time frame: Immediately before stimulation and within 1 hour after stimulation upto 30 days

  7. Duration of Mechanical Ventilation

    Cumulative duration of invasive mechanical ventilation from enrollment until successful liberation from mechanical ventilation, hospital discharge, or death, whichever occurs first. Values will be reported in hours.

    Time frame: From enrollment through hospital discharge, up to 6 months

  8. ICU Length of Stay

    Time from enrollment or intensive care unit admission to intensive care unit discharge or death, reported in hours.

    Time frame: From enrollment through intensive care unit discharge, up to 6 months

  9. Hospital Length of Stay

    Time from hospital admission to hospital discharge or in-hospital death, reported in hours.

    Time frame: From hospital admission through hospital discharge, up to 6 months

  10. In-Hospital Mortality

    Number and percentage of participants who die before hospital discharge.

    Time frame: From enrollment through hospital discharge, up to 6 months

  11. Adverse Events Related to the Procedure or Device

    Number and percentage of participants experiencing adverse events considered possibly, probably, or definitely related to epidural electrode implantation or spinal cord stimulation, including infection, bleeding or hematoma, cerebrospinal fluid leakage, neurological injury, device malfunction, stimulation-related discomfort, or other complications.

    Time frame: From implantation through the 6-month follow-up

06

Study locations

3 sites
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100000, China
  • Zhongda Hospital, Southeast University
    Nanjing, Jiangsu 210009, China
    • Fei Peng, Dr. PhD. · Contact · afei0312@163.com · 15950565786
    • Fei Peng, Dr.PhD. · Principal investigator
  • The 904th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army
    Suzhu, Jiangsu 215000, China
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07766681
Lead sponsor
Zhongda Hospital
Collaborators
The 904th Hospital of the People's Liberation Army of China, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Chinese PLA General Hospital
Responsible party
Fei Peng (Sub-Investigator, Zhongda Hospital) — Principal investigator
First posted
Aug 14, 2026
Start date
Aug 5, 2026 (estimated)
Primary completion
Feb 28, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 14, 2026

Study contacts

Fei Peng, PhD. MD.
Contact
afei0312@163.com
15950565786
Yi Li, PhD.
Contact
liyi@@ion.ac.cn
136 6180 0806

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion